No worries if you cannot answer for disclosure reasons, but I am curious where you got the estimations from? Be looking at around $1 million revenues in Oz, that pale in comparison to the some $30 million from the US and $15 million in EU on that basis.
Throw in CelGro Nerve revenues and initial and milestone payments from a J&J partnership and revenues could go exponential pretty quickly, as will the share price of course....these bio-techs prospects are like call options from an investment perspective, one day apt to take off.
FDA significance, page-405
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
46.0¢ |
Change
-0.005(1.08%) |
Mkt cap ! $96.40M | |||
| Open | High | Low | Value | Volume |
| 46.8¢ | 47.0¢ | 46.0¢ | $37.16K | 79.64K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | 45.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.5¢ | 4123 | 2 |
View Market Depth
| Last trade - 15.28pm 17/09/2024 (20 minute delay) ? |
| OCC (ASX) Chart |